
August 03, 2023
Alliance Nickel Limited (Alliance or the Company) (ASX:AXN) is pleased to advise that it has been notified by Stellantis N.V (Stellantis) that it has received clearance (without conditions) from the Australian Foreign Investment Review Board (FIRB) to undertake the second tranche of the strategic placement with Alliance announced in May 2023 (refer Alliance ASX release dated 1 May 2023, Alliance Nickel executes Binding Offtake Agreement and Cornerstone Equity Investment with Stellantis N.V.).
Highlights
- Tranche 2 new equity proceeds of A$2.3 million expected in September 2023
- Completion will increase Stellantis’ total equity investment in Alliance (at A$0.18 per share) to A$15 million
Settlement of the Tranche 2 placement is expected to take place in early September 2023. It will see Alliance issue 12,733,333 new ordinary shares at A$0.18 per share for receipt of further equity funds of approximately A$2.3 million. The shares will be issued pursuant to the Company’s ASX Listing Rule 7.1 capacity.
Upon settlement of the Tranche 2 placement, Stellantis will have subscribed for a total of A$15 million (at A$0.18 per share) under the strategic placement and will hold an approximate 11.5% interest in Alliance.
The Company continues to strongly advance all major workstreams for development of the NiWest Nickel Project and expects the definitive feasibility study to be released in Q4 2023. In parallel, the Company continues to advance discussions with other potential Tier 1 strategic partners and the project financing process is well underway.
Click here for the full ASX Release
This article includes content from Alliance Nickel, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
The Conversation (0)
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00